Increase in work productivity of depressed individuals with improvement in depressive symptom severity

Madhukar H. Trivedi, David W. Morris, Stephen R. Wisniewski, Ira Lesser, Andrew A. Nierenberg, Ella Daly, Benji T. Kurian, Bradley N. Gaynes, G. K. Balasubramani, A. John Rush

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective: The authors sought to identify baseline clinical and sociodemographic characteristics associated with work productivity in depressed outpatients and to assess the effect of treatment on work productivity. Method: Employed depressed outpatients 18-75 years old who completed the Work Productivity and Activity Impairment scale (N=1,928) were treated with citalopram (20-40 mg/day) in the Sequenced Treatment Alternatives to Relieve Depression study. For patients who did not remit after an initial adequate antidepressant trial (level 1), either a switch to sertraline, sustained-release bupropion, or extendedrelease venlafaxine or an augmentation with sustained-release bupropion or buspirone was provided (level 2). Participants' clinical and demographic characteristics and treatment outcomes were analyzed for associations with baseline work productivity and change in productivity over time. Results: Education, baseline depression severity, and melancholic, atypical, and recurrent depression subtypes were all independently associated with lower benefit to work productivity domains. During level 1 treatment, work productivity in several domains improved with reductions in depressive symptom severity. However, these findings did not hold true for level 2 outcomes; there was no significant association between treatment response and reduction inwork impairment. Resultswere largely confirmed when multiple imputations were employed to address missing data. During this additional analysis, an association was also observed between greater impairment in work productivity and higher levels of anxious depression. Conclusions: Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity. In contrast, patients who achieved symptom remission in second-step treatment continued to have impairment at work. Patients who have demonstrated some degree of treatment resistance are more prone to persistent impairment in occupational productivity, implying a need for additional, possibly novel, treatments.

Original languageEnglish (US)
Pages (from-to)633-641
Number of pages9
JournalAmerican Journal of Psychiatry
Volume170
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Depression
Bupropion
Therapeutics
Outpatients
Buspirone
Sertraline
Citalopram
Productivity
Depressive Symptoms
Antidepressive Agents
Demography
Education
Impairment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)
  • Medicine(all)

Cite this

Increase in work productivity of depressed individuals with improvement in depressive symptom severity. / Trivedi, Madhukar H.; Morris, David W.; Wisniewski, Stephen R.; Lesser, Ira; Nierenberg, Andrew A.; Daly, Ella; Kurian, Benji T.; Gaynes, Bradley N.; Balasubramani, G. K.; Rush, A. John.

In: American Journal of Psychiatry, Vol. 170, No. 6, 01.06.2013, p. 633-641.

Research output: Contribution to journalArticle

Trivedi, MH, Morris, DW, Wisniewski, SR, Lesser, I, Nierenberg, AA, Daly, E, Kurian, BT, Gaynes, BN, Balasubramani, GK & Rush, AJ 2013, 'Increase in work productivity of depressed individuals with improvement in depressive symptom severity', American Journal of Psychiatry, vol. 170, no. 6, pp. 633-641. https://doi.org/10.1176/appi.ajp.2012.12020250
Trivedi, Madhukar H. ; Morris, David W. ; Wisniewski, Stephen R. ; Lesser, Ira ; Nierenberg, Andrew A. ; Daly, Ella ; Kurian, Benji T. ; Gaynes, Bradley N. ; Balasubramani, G. K. ; Rush, A. John. / Increase in work productivity of depressed individuals with improvement in depressive symptom severity. In: American Journal of Psychiatry. 2013 ; Vol. 170, No. 6. pp. 633-641.
@article{b127f2c24eb442608c986de1e153507d,
title = "Increase in work productivity of depressed individuals with improvement in depressive symptom severity",
abstract = "Objective: The authors sought to identify baseline clinical and sociodemographic characteristics associated with work productivity in depressed outpatients and to assess the effect of treatment on work productivity. Method: Employed depressed outpatients 18-75 years old who completed the Work Productivity and Activity Impairment scale (N=1,928) were treated with citalopram (20-40 mg/day) in the Sequenced Treatment Alternatives to Relieve Depression study. For patients who did not remit after an initial adequate antidepressant trial (level 1), either a switch to sertraline, sustained-release bupropion, or extendedrelease venlafaxine or an augmentation with sustained-release bupropion or buspirone was provided (level 2). Participants' clinical and demographic characteristics and treatment outcomes were analyzed for associations with baseline work productivity and change in productivity over time. Results: Education, baseline depression severity, and melancholic, atypical, and recurrent depression subtypes were all independently associated with lower benefit to work productivity domains. During level 1 treatment, work productivity in several domains improved with reductions in depressive symptom severity. However, these findings did not hold true for level 2 outcomes; there was no significant association between treatment response and reduction inwork impairment. Resultswere largely confirmed when multiple imputations were employed to address missing data. During this additional analysis, an association was also observed between greater impairment in work productivity and higher levels of anxious depression. Conclusions: Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity. In contrast, patients who achieved symptom remission in second-step treatment continued to have impairment at work. Patients who have demonstrated some degree of treatment resistance are more prone to persistent impairment in occupational productivity, implying a need for additional, possibly novel, treatments.",
author = "Trivedi, {Madhukar H.} and Morris, {David W.} and Wisniewski, {Stephen R.} and Ira Lesser and Nierenberg, {Andrew A.} and Ella Daly and Kurian, {Benji T.} and Gaynes, {Bradley N.} and Balasubramani, {G. K.} and Rush, {A. John}",
year = "2013",
month = "6",
day = "1",
doi = "10.1176/appi.ajp.2012.12020250",
language = "English (US)",
volume = "170",
pages = "633--641",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "6",

}

TY - JOUR

T1 - Increase in work productivity of depressed individuals with improvement in depressive symptom severity

AU - Trivedi, Madhukar H.

AU - Morris, David W.

AU - Wisniewski, Stephen R.

AU - Lesser, Ira

AU - Nierenberg, Andrew A.

AU - Daly, Ella

AU - Kurian, Benji T.

AU - Gaynes, Bradley N.

AU - Balasubramani, G. K.

AU - Rush, A. John

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Objective: The authors sought to identify baseline clinical and sociodemographic characteristics associated with work productivity in depressed outpatients and to assess the effect of treatment on work productivity. Method: Employed depressed outpatients 18-75 years old who completed the Work Productivity and Activity Impairment scale (N=1,928) were treated with citalopram (20-40 mg/day) in the Sequenced Treatment Alternatives to Relieve Depression study. For patients who did not remit after an initial adequate antidepressant trial (level 1), either a switch to sertraline, sustained-release bupropion, or extendedrelease venlafaxine or an augmentation with sustained-release bupropion or buspirone was provided (level 2). Participants' clinical and demographic characteristics and treatment outcomes were analyzed for associations with baseline work productivity and change in productivity over time. Results: Education, baseline depression severity, and melancholic, atypical, and recurrent depression subtypes were all independently associated with lower benefit to work productivity domains. During level 1 treatment, work productivity in several domains improved with reductions in depressive symptom severity. However, these findings did not hold true for level 2 outcomes; there was no significant association between treatment response and reduction inwork impairment. Resultswere largely confirmed when multiple imputations were employed to address missing data. During this additional analysis, an association was also observed between greater impairment in work productivity and higher levels of anxious depression. Conclusions: Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity. In contrast, patients who achieved symptom remission in second-step treatment continued to have impairment at work. Patients who have demonstrated some degree of treatment resistance are more prone to persistent impairment in occupational productivity, implying a need for additional, possibly novel, treatments.

AB - Objective: The authors sought to identify baseline clinical and sociodemographic characteristics associated with work productivity in depressed outpatients and to assess the effect of treatment on work productivity. Method: Employed depressed outpatients 18-75 years old who completed the Work Productivity and Activity Impairment scale (N=1,928) were treated with citalopram (20-40 mg/day) in the Sequenced Treatment Alternatives to Relieve Depression study. For patients who did not remit after an initial adequate antidepressant trial (level 1), either a switch to sertraline, sustained-release bupropion, or extendedrelease venlafaxine or an augmentation with sustained-release bupropion or buspirone was provided (level 2). Participants' clinical and demographic characteristics and treatment outcomes were analyzed for associations with baseline work productivity and change in productivity over time. Results: Education, baseline depression severity, and melancholic, atypical, and recurrent depression subtypes were all independently associated with lower benefit to work productivity domains. During level 1 treatment, work productivity in several domains improved with reductions in depressive symptom severity. However, these findings did not hold true for level 2 outcomes; there was no significant association between treatment response and reduction inwork impairment. Resultswere largely confirmed when multiple imputations were employed to address missing data. During this additional analysis, an association was also observed between greater impairment in work productivity and higher levels of anxious depression. Conclusions: Patients with clinically significant reductions in symptom severity during initial treatment were more likely than nonresponders to experience significant improvements in work productivity. In contrast, patients who achieved symptom remission in second-step treatment continued to have impairment at work. Patients who have demonstrated some degree of treatment resistance are more prone to persistent impairment in occupational productivity, implying a need for additional, possibly novel, treatments.

UR - http://www.scopus.com/inward/record.url?scp=84882248167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882248167&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2012.12020250

DO - 10.1176/appi.ajp.2012.12020250

M3 - Article

C2 - 23558394

AN - SCOPUS:84882248167

VL - 170

SP - 633

EP - 641

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 6

ER -